38 °C(Solv: methanol (67-56-1); water (7732-18-5))
沸点:
163.5 °C(Press: 17 Torr)
密度:
1.186±0.06 g/cm3(Predicted)
计算性质
辛醇/水分配系数(LogP):
2.4
重原子数:
14
可旋转键数:
2
环数:
2.0
sp3杂化的碳原子比例:
0.18
拓扑面积:
39.4
氢给体数:
0
氢受体数:
3
反应信息
作为反应物:
描述:
3-acetoxy-6-methyl-benzofuran 以
盐酸 、 甲醇 、 水 为溶剂,
反应 1.5h,
以to give 6-methyl-2,3-dihydro-1-benzofuran-3-one as a white solid (2.5 g, 82%)的产率得到6-甲基-3(2H)-苯并呋喃酮
Synthesis, antibacterial activity, and quantitative structure–activity relationships of new (Z)-2-(nitroimidazolylmethylene)-3()-benzofuranone derivatives
摘要:
A new series of (Z)-2-(1-methyl-5-nitroimidazole-2-ylmethylene)-3(2H)-benzofuranones (11a-p) and (Z)-2-(1-methyl-4-nitroimidazole-5-ylmethylene)-3(2H)-benzofuranones (12a-m) were synthesized and assayed for their antibacterial activity against Gram-positive and Gram-negative bacteria. Most of the 5-nitroimidazole analogues (11a-p) showed a remarkable inhibition of a wide spectrum of Gram-positive bacteria (Staphylococcus aureus, Streptococcus epidermidis, MRSA, and Bacillus subtilis) and Gram-negative Klebsiella pneumoniae, whereas 4-nitroimidazole analogues (12a-m) were not effective against selected bacteria. The quantitative structure-activity relationship investigations were applied to find out the correlation between the experimentally evaluated activities with various parameters of the compounds studied. The QSAR models built in this work had reasonable predictive power and could be explained by the observed trends in activities. (C) 2007 Elsevier Ltd. All rights reserved.
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
Substituted quinoxaline carboxylic acids for the inhibition of PASK
申请人:McCall John M.
公开号:US08912188B2
公开(公告)日:2014-12-16
Disclosed herein are substituted quinoxaline carboxylic acids of Formula (I):
and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.